Andrew Fisher Joins Verona Pharma as General Counsel Verona Pharma announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team.

Michael Austwick Joins Verona Pharma as Non-Executive Director LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. ...

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023 PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON...

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and...

Luigi Franciosi to Advise on New Asthma & COPD Drug Development Programs for Vicenna Pharmaceuticals Inc. VANCOUVER, British Columbia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Franciosi Consulting Ltd. (“FCL”) is pleased to announce that its President and CEO, Dr. Luigi Franciosi, has been retained as a...